glp 1 agonist binge eating disorder The rapid rise of GLP-1 receptor agonists presents a complex dilemma for clinicians managing patients with disorders. While these medications show potential in reducing eating behaviors by targeting brain reward GLP-1 receptor agonists are proving

Kim W, Egan JM

( 10.1111/bph.13009) [DOI] [PMC free article] [PubMed] [Google Scholar] Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancakova A, Chen Y, Varga TV, et al

Taken together, the available evidence supports the hypothesis that GLP-1R agonists may attenuate select components of opioid reinforcement, relapse, and withdrawal

These shortages reflect production pressure and increase the supply chain pressures

On average, people lose 15% of their body weight on GLP-1s

To manage symptoms effectively: Start with a low dose and titrate slowly Encourage smaller, low-fat meals Consider changing the dosing schedule or formulation Evaluate other GI causes like gastroparesis if symptoms linger Having regular check-ins helps clinicians identify tolerability issues early and adapt treatment accordingly